15(1)-01(국)(p.1-8).fm

Size: px
Start display at page:

Download "15(1)-01(국)(p.1-8).fm"

Transcription

1 w wz 15«1y Kor. J. Clin. Pharm., Vol. 15, No $MPQJEPHSFM y x y z e w ½ Á w w w w p q ƒ Effects of Drug Interaction with Clopidogrel on Cardiovascular Events and Side Effects Sung Hee KimG and Sukhyang Lee Graduate School of Clinical Pharmacy, Sookmyung Women s University, Seoul, Korea Clopidogrel is used to reduce the risk of cardiovascular events in patients with atherosclerosis documented by recent ischemic stroke, recent myocardial infarction (MI), or established peripheral arterial disease (secondary prevention). Clopidogrel is metabolized by CYP3A4, and the active metabolites inhibit platelet aggregation. The purpose of this study was to assess clopidogrel only versus clopidogrel + others (aspirin, CYP3A4 inhibitor, and CYP3A4 inducer) in terms of cardiovasculalr events and bleeding complications. We reviewed the charts of patients who visited between August 1, 2002 and August 31, 2003, retrospectively. Total 72 patients were included and they consisted of 5 groups; clopidogrel group (n=36), clopidogrel + aspirin group (n=11), clopidogrel + CYP3A4 inhibitor group (n=15), clopidogrel + aspirin + CYP3A4 inhibitor group (n=6), clopidogrel + CYP3A4 inducer group (n=4). The primary endpoints at 6 months, 12 months were the composite of cardiovascular (CV) events. The secondary endpoint was the incidence of bleeding events at 6months, and 12months. At 12months, the primary endpoint was not significantly different among the five groups (p=0.056). In comparison of two groups as clopidogrel only versus clopidogrel + others (aspirin, CYP3A4 inhibitor, and CYP3A4 inducer), the primary endpoint was significantly different (p=0.02). The CV events were increased in the clopidogrel + others group. The secondary end point was not significantly different among the five groups (p=0.52). However, time to bleeding events was in the clopidogrel group and 74.7 in the clopidogrel + others group (p = 0.046). In conclusion, clopidogrel interaction with aspirin, CYP3A4 inhibitor, and CYP3A4 inducer affected cardiovascular events and bleeding events. Drug interaction of clopidogrel with concurrent medications should be considered cautiously. Key words TG clopidogrel, cardiovascular events, bleeding events Clopidogrel MI(Myocardial infarction), ischemic stroke xw y y ù cardiovascular events (fatal or non-fatal ischemic stroke, myocardial infarction, other vascular deaths) w 2 š. 1,2,3) Clopidogrel thienopyridine ticlopidine w x q w. Clopidogrel y y x q w ùkü. y ADP ƒ w w platelet fibrinigen receptor(gp II b /III a ) y w. Correspondence to : w Pharm. D. w w w p q 2ƒ ( ) Tel: , Fax: slee@sdic.sookmyung.ac.kr 4,5,6) clopidogrel ticlopidine w wš ƒ w x q z w. w clopidogrel 300mg w (loading dose) n x w x x ƒ j. 3) CAPRIE clopidogrel aspirin cardiovascular events x z g. Clopidogrel 2) aspirin cardiovascular events 8.7% j x w. w n cardiovascular events z ƒ ƒ w. Aspirin cycloxygenase ww x q w, clopidogrel ADP» mw x q w wx q ƒ z ùkü. 7) PCI-CURE unstable angina non-q-wave MI y w aspirin aspirin clopidogrel w z w. Aspirin 1

2 2 Kor. J. Clin. Pharm., Vol. 15, No. 1, 2005 clopidogrel n stroke w x 1.5% w ù x aspirin n w. 8,9) Clopidogrel ticlopidine w x q z ƒ, onset time. 3,10) Clopidogrel aspirin w, ù aspirin ùkù, x aspirin ƒ. Clopidogrel n x q ùkù» ticlopidine x l «w. 11) w ticlopidine thrombotic thrombocytopenic purpura (TTP) w, clopidogrel šƒ š» w ticlopidine clopidogrel wš. 12,13) t clopidogrel atorvastatin w x q šƒ. 14,15,16,17) Clopidogrel CYP3A4 w 18), CYP3A4 w atorvastatin w clopidogrel x q w š w. w clopidogrel atorvastatin w x q z ƒ š, clopidogrel CYP3A4 n clopidogrel z cardiovascular events e w ù x w šƒ. clopidogrel CYP3A4 y aspirin n cardiovascular events bleeding e z š w. 1 ƒ cardiovascular events wš w, 2 ƒ clopidogrel ƒ j x, x wš w. clopidogrel n k n w cardiovascular events bleeding events wš w l ¾ w clopidogrel 75mg w y y,» mw zw w. Clopidogrel n, aspirin, CYP 3A4 inhibitor, CYP3A4 inhibior + aspirin, CYP3A4 inducer n ƒƒ Group I, II, III, IV, V w. 1) sw» 18 clopidogrel n y 1 ƒ w y w. 2)» 18 w, aspirin, clopidogrel wx q wx š ƒ w y w. x x q (< 150,000/mm 3 ) y ù w y(alt, AST > normal upper limit 3 ) y(serum creatinine > 2 mg/dl) y w. w clopidogrel l y x x y w. sƒü clopidogrel y,» w clopidogrel, clopidogrel + aspirin, clopidogrel + CYP3A4 inhibitor, clopidogrel + CYP3A4 inhibitor + aspirin, clopidogrel + CYP3A4 inducer (Group I, II, III, IV, V) ù š ƒ y» p w» w w w., y» p w» w ƒ y,» wš, œ y v x (Percutaneous Transluminal Coronary Angioplasty, w PTCA) x w., cardiovascular eventsƒ 6, 12 cardiovascular events, w sƒ w. cardiovascular events, x, (Q - wave non Q - wave),, x (revascularization) sww. x» chest pain(+), angina(+)» w š, creatine kinase(ck), CK-MB, LDH, AST ƒ we 2 ƒw w š, x 2,14) ù w w. x (revascularization) lp z CABG(Coronary Artery Bypass Grafting)ù PTCA(Percutaneous Transluminal Coronary Angioplasty) w. lp x (restenosis) lp wš 6 ù z wy y lp w ü 50% w. 2,3), x sƒw» w x w hemoglobin(hb), hematocrit(hct), platelet(plt), hematuria PT, aptt, INR clopidogrel 6 z, 12 z e w. x w x major bleeding minor bleeding w. Major bleeding ü x(intracranial hemorrhage), x w x, ü x, y x, x q (<100,000/mm 3 ), n x, hemoglobin eƒ baseline w 3g/dl ƒ, x

3 Clopidogrel y x y z e w 3 3 unit,» x < 90mmHg, w x ƒ 2 w w. Minor bleeding x, x, ü x major bleeding x w. 8, 9 ƒ y p t-test, ANOVA chi-square test w. ƒ cardiovascular events x y ùküš chi-square test w. m SPSS (version 11.5) t test ANOVA w š, p-value 0.05 w m w l ¾ clopidogrel 75mg w y ƒ w y 72 clopidogrel n 36, k n w 36. k clopidogrel n 36 aspirin (Group II) 11, CYP3A4 inhibitor (Group III) 15, CYP3A4 inhibitor + aspirin (Group IV) 6, CYP3A4 inducer (Group V) 4. CYP3A4 inhibitor bromocriptine, atorvastatin, paroxetine, cimetidine, verapamil, sertraline, diazepam n w š, CYP3A4 inducer primidone, carbamazepine n w. y p y» p ƒ y ù,, PT, aptt, INR, Hb, Plt, Hct» p w ƒ. Group I s³ 62.6±1.6 ƒ û š, 60. (Female/ Male-%) û, Group III û. PT, aptt, INR, Hb, Plt, Hct ù e ü m w. w, PTCA, œ y ƒ ƒ (Table 1). $BSEJPWBTDVMBS $7FWFOUT CV events clopidogrel n (Group I) clopidogrel k n (Group II, III, IV, V) ù r. Clopidogrel n 8 (22%), clopidogrel k n 17 (47%) CV eventsƒ w (p=0.02). Clopidogrel n, clopidogrel k n Table 1. Baseline characteristics of patients characteristics Group I Group II Group III Group IV Group V (n = 36) (n = 11) (n = 15) (n = 6) (n = 4) P value Age yr 62.6 ± ± ± ± ± Sex (F/M) - % 38.8/ / / / / PT - sec 14.2 ± ± ± ± ± aptt - sec 36.4 ± ± ± ± ± INR 1.09 ± ± ± ± ± Hb 13.4 ± ± ± ± ± Plt 232 ± ± ± ± ± Hct 39.8 ± ± ± ± ± Prior infarction - No. (%) 29 (80.6) 10 (90.9) 12 (80) 6 (100) 2 (50) 0.31 Prior PTCA - No. (%) 7 (19.4) 5 (45.5) 1 (6.7) 2 (33.3) 0 (0) 0.11 œ y - No Coronary Heart - Disease Congestive Heart - Failure Atrial fibrillation Hypertension Diabetes Hyperlipidemia *group I = clopidogrel group II = clopidogrel + aspirin group III = clopidogrel + CYP3A4 inhibitor group IV = clopidogrel + CYP3A4 inhibitor + aspirin group V = clopidogrel + CYP3A4 inducer

4 4 Kor. J. Clin. Pharm., Vol. 15, No. 1, 2005 ƒƒ stroke(4, 6 ), Congestive heart failure (CHF) (1, 2 ), restenosis(3, 3 ) w š, k n unstable angina 2, cerebral infarction 4 w. Myocardial infarction (MI) ùkù.(table 2, Fig. 1) Clopidogrel n Group I, II, III, IV, V w, CV events w. Clopidogrel (Group I) 8 (22%), aspirin (Group II) 5 (45%), CYP3A4 inhibitor (Group III) 9 (60%), aspirin + CYP3A4 inhibitor (Group IV) 3 (50%) w š, CYP3A4 inducer (Group V) CV eventsƒ w.(p=0.056)(table 2, Fig. 2) CV eventsƒ clopidogrel n s³ 122.8±74, clopidogrel k n 144.5±99 ùkûš, clopidogrel n, k n clopidogrel n 16 CV eventsƒ w. CV events ù r. Group I ƒƒ (4, 4 ), Group II (2, 3 ), Group III (6, 3 ), Group IV (1, 2 ) ùkûš, Group V ùkù. CV events p=0.68 m w (Table 3). #MFFEJOHFWFOUT Bleeding event clopidogrel n (Group I) clopidogrel k n (Group II, III, IV, V) ù r. Clopidogrel Fig. 1. Cardiovascular event of clopidogrel treatment: stroke, CHD, MI, restenosis. n 15 (41%), clopidogrel k n 19 (52%) bleeding eventsƒ w (p=0.34). Minor bleeding ƒƒ(7,12 ), major bleeding (8, 7 ) w.(table 4, Fig. 4) Clopidogrel n Group I, II, III, IV, V w bleeding events w. Group I 15 (41%), Group II 5 (45%), Group III 9 (60%), Group IV 2 (33%), Group V 3 (75%) bleeding eventsƒ w (p=0.45) (Table 4, Fig. 3). Table 2. Cardiovascular events at 12months of clopidogrel treatment stroke CHD restenosis CHF total Clopidogrel only Group I Clopidogrel + others Group II Group III Group IV Group V Total *Group I / II / III / IV / V p=0.056 *Clopidogrel / clopidogrel+others p=0.02 * *CHD = coronary heart disease *group I = clopidogrel *group II = clopidogrel + aspirin *group III = clopidogrel + CYP3A4 inhibitor group IV = clopidogrel +CYP3A4 inhibitor + aspirin *group V = clopidogrel + CYP3A4 inducer Fig. 2. Cardiovascular events of each group with clopidogrel treatment : stroke, CHD, MI, restenosis.

5 Clopidogrel y x y z e w 5 Table 3. Site of cardiovascular events at 12months of clopidogrel treatment Brain Heart Total Group I Group II Group III Group IV Group V Total *group I = clopidogrel group II = clopidogrel + aspirin group III = clopidogrel + CYP3A4 inhibitor group IV = clopidogrel + CYP3A4 inhibitor + aspirin group V = clopidogrel + CYP3A4 inducer Table 4. Bleeding events at 12months of clopidogrel treatment Minor bleeding Major bleeding total Clopidogrel only Group I Fig. 3. Bleeding events of each group with clopidogrel treatment. Clopidogrel + others Group II Group III Group IV Group V Total *group I = clopidogrel group II = clopidogrel + aspirin group III = clopidogrel + CYP3A4 inhibitor group IV = clopidogrel + CYP3A4 inhibitor + aspirin group V = clopidogrel + CYP3A4 inducer ƒ minor bleeding, major bleeding Group I (7, 8 ), Group II(2, 3 ), Group III(7, 2 ), Group IV(2, 0 ), Group V(1, 2 ) w (Table 4). Minor bleeding x, x š, major bleeding GI bleeding, ICH(Intracranial hemorrhage)ƒ. Bleeding eventsƒ clopidogrel n s³ 230.8±120 ùkûš, clopidogrel k n 74.7±95 ùkû m w ùkþ (p=0.046). Clopidogrel n 14 bleeding ùkû, clopidogrel k n 10 bleeding ùkû. Bleeding event x w Hb, Hct, aptt, PT, INR, Plt y 6, 12 w. Hgb clopidogrel n clopidogrel k n 6 (0.14 g/dl, 0.48 g/dl) w š, 12 n base-line ƒ w ù clopidogrel k n 2.15 g/dl Fig. 4. Bleeding events of clopidogrel treatment. e(13-17 g/dl) û ùkû. Hct clopidogrel n k n 6 (0.6%, 3.34%) w š, 12 n base-line ƒ w ù k n 5.74% e (39-52%) û ù kû (Fig. 5). aptt clopidogrel n k n 6 (4.36sec, 8.56sec) ƒw š, 12 n base-line w ù k n 8.35sec ƒ w (Fig. 6). PT clopidogrel n 6, 12 base-line w ù k n sec, sec ƒw e(11-15 sec) ùkû (Fig. 7). INR clopidogrel n 6, 12

6 6 Kor. J. Clin. Pharm., Vol. 15, No. 1, 2005 Fig. 5. Hematocrit(Hct) of clopidogrel treatment. Fig. 8. Platelet of clopidogrel treatment. Fig. 6. aptt of clopidogrel treatment. Fig. 7. INR of clopidogrel treatment. base-line w ù, k n , ƒ w ù ( )ü. Plt clopidogrel n, k n 6 ( /µl, /µl) ƒ 3 w š, 12 ( /µl, /µl) ƒw ù ( /µl) 3 yw (Fig. 8). š y y» wx q lp x ù x w» w v w ACCP (American college of Chest Physicians) IV e w lp z wx aspirin mg ticlopidine w 500mg n z 250 mg 1 2z n w ù clopidogrel w 300mg n z 75 mg n w wš. 19) Ticlopidine w, x q, l w «šwš» ticlopidine w w w t š clopidogrel ƒw š. 3) Clopidogrel ticlopidine w CLASSICS 3), Pache ƒ w 20) clopidogrel ticlopidine w z š w. Clopidogrel aspirin w PCI-CURE 8) CAPRIE ƒ 2). PCI-CURE unstable angina y ù non-q-wave MI y ww aspirin clopidogrel z w š, clopidogrel w y w. aspirin n sww» CAPRIE w. CAPRIE clopidogrel aspirin n CV events z ƒ w, clopidogrel n (Group I) clopidogrel + aspirin n (Group II) w ƒ ù. Group I 36 8 (22.2%) CV

7 Clopidogrel y x y z e w 7 eventsƒ w ù Group II 11 5 (45.4%) w clopidogrel aspirin n CV events w ùkù. ù Group I II Group III IV w, clopidogrel aspirin n CV events û ùkû. Group IV 6 3 (50%) CV events ƒ Group III 15 9 (60%) CV events û ùkû. ƒ Group III IV aspirin clopidogrel n ƒ CV events û CAPRIE ew ùkü. CAPRIE w y ƒ» ƒ. w CLASSICS clopidogrel + aspirin 28 CV eventsƒ % w, (9%) w. Lau WC, Waskell LA 14,15) Clarke TA 16), Victor L, Serebruany 17) atorvastatin clopidogrel n CYP 3A4 inhibitor atorvastatin w clopidogrel y x ƒ û x q û š w. ù x q sƒw š x q w» CV events x q t. CYP 3A4 inhibitor (Group III) 15 9 (60%) CV eventsƒ w ù, CYP3A4 inducer (Group V) CV eventsƒ w w clopidogrel x CYP3A4 w š. Group I II, III, IV, V j ù clopidogrel n CV events 22.2% clopidogrel k n CV events 47.2% û ùkû. CREDO 21) clopidogrel + aspirin bleeding eventsƒ 4.8% w ù Group II 11 5 (45.4%) ùkù ƒ. CURE 8) clopidogrel aspirin n aspirin n w x x š w. aspirin n w, clopidogrel n (Group I) clopidogrel + aspirin (Group II) w (41.6 %) 11 5 (45.4%) aspirin ƒ n w bleeding eventsƒ w. CURE e w. ù Group III 60% bleeding eventsƒ w, Group IV 33% ùkù aspirin n x w. CURE w. w Group III 60% bleeding eventsƒ w š, Group V 75% w. CYP3A4 clopidogrel w bleeding events w š. Bleeding events Group I II, III, IV, V j ù clopidogrel n 41.6%, clopidogrel k n 52.7% ùkû. w bleeding eventsƒ w, clopidogrel k n n w s³ 160 x w. clopidogrel w x ƒ k š ƒ. CAPRIE ƒ 6, w w 72 y ƒ. Clopidogrel n y 300 ƒ¾ ù clopidogrel warfarin y w ù k», CYP3A4 inhibitor inducer ƒ k. w 1» ww» CAPRIE w ƒ ƒ. w platelet aggregation ratio sƒ w w ù ùkü w, platelet aggregation ratio ƒ x šƒ š, clopidogrel warfarin j x x» platelet aggregation ratio ww y ƒ ƒ 1 m w» sƒ w w. zw» mw sƒw y ƒ wš, tw» y ƒ š ƒ. Clopidogrel y w yw w» w wz y sw g w ƒ v w. y y š x ù šg l x œ y. š x ù šg l x atorvastatin š, z w. w d diazepam ù, stroke convulsion» ù d m carbamazepine, primidone CYP3A4 clopidogrel y w š v w. Clopidogrel aspirin, CYP3A4 n w, clopidogrel z e w sƒw. Clopidogrel CYP3A4 inhibitor n CV events m w ƒw š(p=0.02),

8 8 Kor. J. Clin. Pharm., Vol. 15, No. 1, 2005 CYP3A4 inducer n bleeding events ƒw. m w ù Clopidgrel n k n ù w clopidogrel n x w g, x w g. w CV events clopidogrel n, k n w m w (p=0.02) CV events ƒ g. š x 1. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999; 100: CAPRIE steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet. 1996; 348: Bertrand ME, Repprecht HJ, Urban p, et al. Double blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) Circulation 2000; 102: Savi P, Herbert JM, pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992; 44: Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Disp. 2002; 30: Gerger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Yac ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999; 19: Armin J, Grau, Sven Reiners et al. Platelet function under aspirin, clopidogrel, and both after ischemic stroke. Stroke 2003; 34: Shamir R Mehta, Salim Yusuf, Ron J G Peters, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention : the PCI-CURE Study. Lancet 2001; 358: Gregory W. Albers, Pierre Amarenco. Combination therapy with clopidogrel and aspirin. Stroke 2001; 32: Herbert JM, Frehel D, Vallee E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 1993; 11: Gregory W, albers, chair. Supplements to the Guidelines for the management of transient ischemic attacks. Stroke 1999; 30: Steinhubl SR, Tan WA, foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic due to ticlopidine following coronary stenting. JAMA 1999; 281: Charles L, Bennett, Jean M, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. New England J. Medicine 2000; 342: Lau WC, Waskell LA, Watkins PB, et al. Atrovastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A New drug-drug intervention. Circulation 2003; 107: Lau WC, Waskell LA, Neer CJ, et al. The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not pravastatin. Circulation 2000; 102(suppl II): Clarke TA, Waskell LA. The metabolism of clopidogrel is catalysed by human cytochrome P 450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: Victor L, Serebruany, et al. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? Circulation 2003; 107: Sugidachi A, Asai F, Yoneda K, et al. Antiplatelet action of R-99224, an active metabolite of a novel thiopyridine type G1-linked P2T antagonist, CS-747. Br J Pharmacol. 2001; 132: Popma JJ, Ohman EM, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention Chest 2001; 119(suppl): 321s-336s. 20. Pache J, Kastrati A, Mehilli J, et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high loading dose regimen. Cathet Cardiovasc Intervent 2002; 55: Steinhubl SR, berger PB, Topol EJ, et al. Early and sustained dual antiplatelet therapy following percutaneous coronary intervention. JAMA 2002; 288:

15(2)-7.fm

15(2)-7.fm w wz 15«2y Kor. J. Clin. Pharm., Vol. 15, No. 2. 25 lp z$mpqjephsfm $JMPTUB[PM E BCÁ»CDÁ B w w w C s w D s w w E w w w w Comparison of Clopidogrel versus Cilostazol in Coronary Artery Stenting In Sook

More information

16(2)-7(p ).fm

16(2)-7(p ).fm w wz 16«2y Kor. J. Clin. Pharm., Vol. 16, No. 2. 2006 ü t xy y w tœ ½ BÁ x BC B y w w w C y w w w Current Status and Expectations of Orphan Drugs in Korea -In point of supplying medicines for the rare

More information

(Microsoft PowerPoint - CXBTUEOAPVQY.ppt [\310\243\310\257 \270\360\265\345])

(Microsoft PowerPoint - CXBTUEOAPVQY.ppt [\310\243\310\257 \270\360\265\345]) 당뇨병환자에서항혈소판제사용 - 아스피린일차예방을중심으로 - 경희대학교강동경희대병원 황유철 말씀드릴내용 당뇨병및심혈관질환의역학 아스피린의심혈관질환 1차, 2차예방효과 아스피린부작용및용량에따른효과차이 당뇨병환자에서아스피린사용의적응증 사망원인순위, 2010 년 25.6% 통계청 심혈관질환에의한의료비추세 6 조 1400 억 국민건강보험공단, 2002-2009 Multidisciplinary

More information

노영남

노영남 Purpose: Delayed massive hemorrhages from pseudoaneurysm rupture of the peripancreatic large arteries, after pancreaticoduodenectomy, are fatal. We reviewed the clinical course and outcome of bleeding

More information

16(1)-3(국문)(p.40-45).fm

16(1)-3(국문)(p.40-45).fm w wz 16«1y Kor. J. Clin. Pharm., Vol. 16, No. 1. 2006 x w$btf3fqpsu'psn û w m w Department of Statistics, Chonnam National University Eunsik Park College of Natural Sciences, Chonnam National University

More information

304.fm

304.fm Journal of the Korean Housing Association Vol. 20, No. 3, 2009 yw s w - û - A Study on the Planning of Improved-Hanok - Focused on Jeon-Nam Province - y* ** z*** **** Kang, Man-Ho Lee, Woo-Won Jeong, Hun

More information

14.531~539(08-037).fm

14.531~539(08-037).fm G Journal of the Korea Concrete Institute Vol. 20, No. 4, pp. 531~539, August, 2008 š x y w m š gj p { sƒ z 1) * 1) w w Evaluation of Flexural Strength for Normal and High Strength Concrete with Hooked

More information

605.fm

605.fm Journal of the Korean Housing Association Vol. 19, No. 6, 2008 y k y p w sƒ Care-giver s Needs and Evaluation on the Actual Condition of the Playgrounds in Child Care Facilities y* Choi, Mock-Wha x **

More information

Treatment and Role of Hormaonal Replaement Therapy

Treatment and Role of Hormaonal Replaement Therapy Treatment and Role of Hormone Replacement Therapy Chung-Ang University Hospital Chee Jeong Kim 7.2 5.3 6.4 5.6 7.3 5.5 1 1 2 3 4 10 11 7 34 49 122 123 1.0 - - 10. 2001 1998 1998 Improvement of postmenopausal

More information

10(3)-12.fm

10(3)-12.fm w y wz 10«3y 273~280 (2010.12.) Journal of Korean Society of Urban Environment p yá xá½k w y œw (2010 9 15, 2010 12 2 k) Analysis of Characteristics of Delivered Nonpoint Source Pollution at Forested Watershed

More information

10(3)-09.fm

10(3)-09.fm w y wz 10«3y 253~258 (2010.12.) Journal of Korean Society of Urban Environment ³ w Á» Á Á y w y œw (2010 11 22, 2010 12 9 k) Study on Determine of Detention Pond in Small Developed Area In-Soo Chang ½

More information

untitled

untitled Case Report : Asan Medical Center Cardiac Rehabilitation AACVPR (http://www.aacvpr.org/) KACVPR (http://www.kacvpr.com/) Backgrounds PCI 2,395 consecutive patients in Minnesota (Mayo Clinic) Between1994

More information

10(3)-10.fm

10(3)-10.fm w y wz 10«3y 259~264 (2010.12.) Journal of Korean Society of Urban Environment w gj p p y Á Á½k * w m œw Á* w y œw (2010 9 28, 2010 10 12 k) Characteristics of Antiwashout Underwater Concrete for Reduction

More information

9(3)-4(p ).fm

9(3)-4(p ).fm w wz J. Kor. Soc. Cloth. Ind. 9«3y, 2007 Vol. 9, No. 3, pp.319-326(2007) w xk x p w q w Analysis of Foot Characteristics According to the Classification of Foot Types of Junior High School Girls Ji-Young

More information

17.393~400(11-033).fm

17.393~400(11-033).fm Journal of the Korea Concrete Institute Vol. 23, No. 3, pp. 393~400, June, 2011 GGGGG DOI 10.4334/JKCI.2011.23.3.393 x RC { sƒ y y 1) *Á½ 1) Á 2) 1) y w œw 2) w œw Bond Strength Evaluation of RC Beams

More information

12.077~081(A12_이종국).fm

12.077~081(A12_이종국).fm J. of Advanced Engineering and Technology Vol. 1, No. 1 (2008) pp. 77-81 y w» e wx Á w œw Fabrication of Ceramic Batch Composition for Porcelain by Using Recycled Waste Ceramic Powder Hyun Guen Han, and

More information

10(3)-02.fm

10(3)-02.fm w y wz 10«3y 203~211 (2010.12.) Journal of Korean Society of Urban Environment w ù p yá k«áyw *Á xá½k w y œw Á* y w (2010 9 15, 2010 12 2 k) Characterization of Nonpoint Source Pollutant Loads from the

More information

21(1)-5(10-57)p fm

21(1)-5(10-57)p fm w wz 21«1y Kor. J. Clin. Pharm., Vol. 21, No. 1. 2011 m w : w w B Á ³ C B û w w w C û w w w (2010 12 3 Á2011 3 21 Á2011 3 22 ) A Descriptive Research on Drug Use Pattern of Narcotic Analgesics: a Case

More information

69-1(p.1-27).fm

69-1(p.1-27).fm 99 A 380 B 787 : wœ z w * w w wœ» A380 B787 wœ» w. wœ» ww r. w wœ» p j y w r» w. I. II. z III. A380 B787 IV. A380 V. wœ» : x VI. z VII. I. A380 B787»ƒ z wœ w, w w p j w w ƒ r. t wœ w ƒ w w wœ» š œm wš,

More information

(Microsoft PowerPoint - S13-3_\261\350\273\363\307\366 [\310\243\310\257 \270\360\265\345])

(Microsoft PowerPoint - S13-3_\261\350\273\363\307\366 [\310\243\310\257 \270\360\265\345]) Cardiovascular Disease in Metabolic Syndrome 김상현 보라매병원내과 서울대학교의과대학내과학교실 Contents Metabolic syndrome and Cardiovascular system CVD Mortality Coronary artery disease Heart failure Atrial fibrillation Management

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

416.fm

416.fm Journal of the Korean Housing Association Vol. 20, No. 4, 2009 œ qp œ y An Analysis of Change on the Apartment Unit Plans and the Interior Spaces Related to Women * Choi, ByungSook ** Park, JungA "CTUSBDU

More information

12(2)-04.fm

12(2)-04.fm J. Korean. Soc. Living. Environ. Sys. Vol. 12, No. 2, pp 106~111(2005) w y y w z œ k üœ» p ½ Á Á Á ³ Á Á½Ÿ w w w, *g», ** w w Effects of Strategies to Improve Indoor Air Quality at Pre-occupancy Stage

More information

Living Remedy March 2005_Vol.12 elixir 04 SPECIAL THEME 08 Special Theme I 12 Special Theme I I 16 Special Theme I I I C

Living Remedy March 2005_Vol.12 elixir 04 SPECIAL THEME 08 Special Theme I 12 Special Theme I I 16 Special Theme I I I C March 2005_Vol.12 Living Remedy March 2005_Vol.12 elixir 04 SPECIAL THEME 08 Special Theme I 12 Special Theme I I 16 Special Theme I I I 20 23 26 30 36 38 40 42 45 47 Cover Story 04 05 Special Theme Special

More information

< DC1A4C3A5B5BFC7E22E666D>

< DC1A4C3A5B5BFC7E22E666D> ¼ (Jeong, Jung Chae)*, ý (Kim, Yoon Soo), (Shin, Woo Young), Þ Ñ (Park, Jong Man) ò ý ƒ Ð (Korea Evaluation Institute of Industrial Technology) (Shin, Jae-Heyg) Š æ (Ministry of Knowledge Economy) 1. :

More information

12(3) 10.fm

12(3) 10.fm KIGAS Vol. 12, No. 3, September, 2008 (Journal of the Korean Institute of Gas) ü LP ƒ š Database w š Á Á½z w ywœw (2008 6 10, 2008 8 12 (1 ), 2008 9 5 (2 ), 2008 9 5 k) Constructing a Database Structure

More information

82-01.fm

82-01.fm w y wz 8«( 2y) 57~61, 2005 J. of the Korean Society for Environmental Analysis p w w Á Á w w» y l Analysis of Influence Factors and Corrosion Characteristics of Water-pipe in Potable Water System Jae Seong

More information

untitled

untitled ª Œª Œ 27ƒ 2B Á 2007 3œ pp. 193 ~ 199 ª ƒ w d w ƒ sƒ Methodology of Drought Assessment Using National Groundwater Monitoring Network Data «x Á½ Kwon, Hyung JoongÁKim, Seong Joon Abstract The objective

More information

기관고유연구사업결과보고

기관고유연구사업결과보고 기관고유연구사업결과보고 작성요령 2001 ~ 2004 2005 ~ 2007 2008 ~ 2010 2001 ~ 2004 2005 ~ 2007 2008 ~ 2010 1 2/3 2 1 0 2 3 52 0 31 83 12 6 3 21 593 404 304 1,301 4 3 1 8 159 191 116 466 6 11 (`1: (1: 16 33 44 106

More information

1..

1.. Volume 12, Number 1, 6~16, Factors influencing consultation time and waiting time of ambulatory patients in a tertiary teaching hospital Jee-In Hwang College of Nursing Science, Kyung Hee University :

More information

012임수진

012임수진 Received : 2012. 11. 27 Reviewed : 2012. 12. 10 Accepted : 2012. 12. 12 A Clinical Study on Effect of Electro-acupuncture Treatment for Low Back Pain and Radicular Pain in Patients Diagnosed with Lumbar

More information

11(5)-12(09-10)p fm

11(5)-12(09-10)p fm w wz J. Kor. Soc. Cloth. Ind. 11«5y, 2009 Vol. 11, No. 5, pp.799-807(2009) w w * k ƒm w pg p w, ƒm w q w A Qualitative Research on Pursuing Image and Appearance Management Behavior of Brides Eun-Joo Bae

More information

Risk of Developing Hypertension by Daily Intake of Alcohol

Risk of Developing Hypertension by Daily Intake of Alcohol JNC 7 ESH/ESC (Guidelines) Guidelines 2003. 5 JNC 7 Guidelines ; The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA. 2003;289:2560-2572.

More information

DBPIA-NURIMEDIA

DBPIA-NURIMEDIA Printed in the Republic of Korea "/"-:5*$"- 4$*&/$& 5&$)/0-0(: Vol. 18, No. 5, 425-430, 2005» 677*4 Ÿ w sƒ ½»x Á Á½ k w y w, w y œw Some considerations for the analytical approaches to measure atmospheric

More information

00약제부봄호c03逞풚

00약제부봄호c03逞풚 경희대학교 동서신의학병원 약품 정보지 2 0 0 7. S P R I N G. V O L. 0 1 신약 소개 02 Journal Review 03 Special Subject 04 복약 지도 06 의약품 안전성 정보 07 약제부 알림 07 약제부 업무 소개 08 E A S T - W E S T N E O M E D I C A L C E N T E R 본 약품

More information

21(1)-3(10-64)p fm

21(1)-3(10-64)p fm w wz 21«1y Kor. J. Clin. Pharm., Vol. 21, No. 1. 2011 3» y t sƒv e z t ½ Á x Á xk w w w (2010 12 31 Á2011 3 11 Á2011 3 13 ) Comparison of Drug Prescriptions Before and AfterG Computerized Drug Utilization

More information

Lumbar spine

Lumbar spine Lumbar spine CT 32 111 DOI : 10.3831/KPI.2010.13.2.111 Lumbar Spine CT 32 Received : 10. 05. 23 Revised : 10. 06. 04 Accepted : 10. 06. 11 Key Words: Disc herniation, CT scan, Clinical analysis The Clinical

More information

82.fm

82.fm Journal of the Korean Ceramic Society Vol. 44, No. 9, pp. 524~528, 2007. Determination of Critical Chloride Content of Ordinary Portland Cement Concrete by Linear Polarization Technique Hong-Sam Kim, Hai-Moon

More information

8(2)-4(p ).fm

8(2)-4(p ).fm w wz J. Kor. Soc. Cloth. Ind. 8«2y, 2006 Vol. 8, No. 2, pp.177-182(2006) x w e w 1) Á Ÿ 1) Á»û 2) 1) ƒm w q w 2) w w w The Effect of Media on Taking Plastic Surgery Chong-Hee Yun 1), Su-Kwang Sung 1) and

More information

16(2)-10(p ).fm

16(2)-10(p ).fm w wz 16«2y Kor. J. Clin. Pharm., Vol. 16, No. 2. 2006 w t w BÁ½ C B w w w C x sƒ Analysis of Perception on the Bioequivalence-assured Generic Drugs Eui Kyung Lee a G and Dong Sook Kim b a Graduate School

More information

50(1)-09.fm

50(1)-09.fm 2006, Vol. 50, No. 1 Printed in the Republic of Korea 언빨래가마르는현상에대한중등학교화학전공교사들의인식조사 ½x Á» Á½ # Á x* w w yw y š w w # w w (2005. 5. 11 ) A Research of Secondary School Chemistry Major Teachers Perceptions

More information

14(4) 09.fm

14(4) 09.fm J. Korean. Soc. Living. Environ. Sys. Vol. 14, No. 4, pp 343~350(2007) w y y w z 14 «4 y 2007 yw» l s p»xá ³ *w w w œw, **w w w The Property of Pressure Distribution of Hybrid Underfloor Air Distribution

More information

황지웅

황지웅 Comparison of Laparoscopy and Exploration in the Distal Pancreatectomy BACKGROUND: To determine the benefits of laparoscopic surgery compared with exploration, the clinical outcomes of open and laparoscopic

More information

15.101~109(174-하천방재).fm

15.101~109(174-하천방재).fm w wz 8«4y 2008 8 pp. 101 ~ 109 w» m -,, - A Study on Warnning Criteria Investigation of Automated Rainfall Warning System -Focused on Realationship of Water Level, Discharge and Precipitation - Á Á Á Ahn,

More information

fm

fm [ ] w wz DOI: 10.3740/MRSK.2009.19.12.692 Kor. J. Mater. Res. Vol. 19, No. 12 (2009) y INCONEL 718w Gas Tungsten Arc Welding» p sƒ ½»y Á *Á *Á y** ( ) d lj p wœq, *w wœ» q **( ) d lj p t Mechanical Properties

More information

<283732372D3733312920B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A1283035292E687770>

<283732372D3733312920B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A1283035292E687770> 대한안과학회지 제 49 권 제 5 호 2008 J Korean Ophthalmol Soc 49(5):727-731, 2008 DOI : 10.3341/jkos.2008.49.5.727 다초점 소프트콘택트렌즈의 노안의 시력보정에 대한 유용성 평가 김현경 1 김효명 2 정성근 1 가톨릭대학교 의과대학 성모병원 안과학교실 1, 고려대학교 의과대학 안암병원 안과학교실

More information

<30312D303720B9DAC1A4BCF62E666D>

<30312D303720B9DAC1A4BCF62E666D> wz (010), 40«1y J. Kor. Pharm. Sci., Vol. 40, No. 1, 1-7 (010) 생물학적동등성시험을위한통계처리프로그램 (BioEquiv) 의개발 z 1 Áyù Á 3 Á 4 Á 1 1 û w m w, w wx, 3 û w w w, 4 û w w w (009 11 0 Á09 1 11 Á010 1 6 ) Developmet of

More information

서론 34 2

서론 34 2 34 2 Journal of the Korean Society of Health Information and Health Statistics Volume 34, Number 2, 2009, pp. 165 176 165 진은희 A Study on Health related Action Rates of Dietary Guidelines and Pattern of

More information

Abstract Background : Most hospitalized children will experience physical pain as well as psychological distress. Painful procedure can increase anxie

Abstract Background : Most hospitalized children will experience physical pain as well as psychological distress. Painful procedure can increase anxie Volume 12, Number 1, 92~102, An Intervention Study of Pain Reduction during IV Therapy in Hospitalized Children Myo-Jin Kim 1), Joung-Hae Bak 1), Won-Seok Seo 2) Mi-Young Kim 3), Sun-Kyoung Park 3), Jai-Soung

More information

( )Jkstro011.hwp

( )Jkstro011.hwp 비인강암의방사선치료결과및생존율에관한예후인자분석 2005 2 1 2005 3 28. :, Tel: 053)250-7665, Fax: 053)250-7984 E-mail: jhkim@dsmc.or.kr 정영연외 2 인 : 비인강암의예후인자분석 정영연외 2 인 : 비인강암의예후인자분석 Carcinoma of the nasopharynx treated by radiotherapy

More information

16(1)-9(국문)(p.46-51).fm

16(1)-9(국문)(p.46-51).fm w wz 16«1y Kor. J. Clin. Pharm., Vol. 16,. 1. 2006 x y x B»C s w s w w Pattern and Management of Dyslipidemia in Type 2 Diabetes Patients in Korea Kyong Ju Jeong a and Seung Ki Cho b a Dept of Pharmacy,

More information

untitled

untitled [ ] œwz, 21«6y(2008) J. of the Korean Society for Heat Treatment, Vol. 21, No. 6, (2008) pp. 300~306 š y w p x*, **Á **Áy y* * ** w œ w œw, w» gœ Solid State Diffusion Brazing of the Aluminum Alloy Castings

More information

16(1)-4(국문)(p.9-13).fm

16(1)-4(국문)(p.9-13).fm w wz 16«1y Kor. J. Clin. Pharm., Vol. 16, No. 1. 2006 w w w BÁy CÁ wšdá DÁ DÁ ³D B C û w w w D û w w w Survey Analysis of Familiarity and Willingness of the Use of Auxiliary Label in Community Pharmacists

More information

페링야간뇨소책자-내지-16

페링야간뇨소책자-내지-16 야간뇨의진단과치료 - 실제적접근 - Reference 1. Choo MS, Ku JH, Park CH et al. Prevalence of Nocturia in a Korean Population Aged 40 to 89 Years. Neurourol Urodyn 2008; 27:60-64. 2. Weiss JP. Prevalence

More information

<30332DB9E8B0E6BCAE2E666D>

<30332DB9E8B0E6BCAE2E666D> kœw» y w k p y w k» z wš ye z w mdkqvqrg üœ» y» Ÿ w kœwgeqgpikpggtkpiy glj GEQVGEJPQNQI[ œw w k w yz š y j œ w m w y ˆ mw y» kœ w k û ³ y ƒ ƒ» ƒ w œw w w y ƒƒ» k z w» %NGCP 9CVGT #EV wšw y ù» œ w w w t

More information

50(5)-07.fm

50(5)-07.fm Printed in the Republic of Korea w 3w yû x w w w Á x* w w w yw (2006. 3. 14 ) A research of the Difference in Teaching Styles and Understanding of 9 th Grade Students About Lead-iodide Precipitation Reaction

More information

10(1)-08.fm

10(1)-08.fm w y wz 10«( 1y) 47~52, 2007 J. of the Korean Society for Environmental Analysis œ w t y ½ xá Á x Á½ Á x* Ÿ œ, * w œw Optimization of Coagulation In The Conventional Water Treatment Plant Jun-Hyun Kim,

More information

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee University College of Medicine & Hospital E mail : ycell2@yahoo.co.kr Abstract

More information

심장2.PDF

심장2.PDF (Treatment of Hypertension with Associated Diseases) 1.. (140/90 mmhg). 80 mmhg. ( ). (atenolol ), (amlodipine ) 1. -1 nitrate. ACE diltiazem, verapamil. ACE. ( )., ACE diltiazem,, diltiazem, verapamil.

More information

31(3B)-07(7055).fm

31(3B)-07(7055).fm ª Œª Œ 31ƒ 3B Á 2011 5œ pp. 265 ~ 276 ª w w s³ The Correlation Between the Moving Average of Precipitation and Groundwater Level in Korea Á½û» Yang, Jeong-SeokÁKim, Nam-Ki Abstract Precipitation data and

More information

32(4B)-04(7455).fm

32(4B)-04(7455).fm 32«4ByÁ 2012 7 pp. 233 ~ 242 œ w w w y œ r Estimation of Domestic Water Supply Benefit Using Demand Function Approach ³ Á Á½¼yÁ Yeo, Kyu DongÁYi, Choong SungÁKim, Gil HoÁLee, Sang Won Abstract In the past,

More information

한국성인에서초기황반변성질환과 연관된위험요인연구

한국성인에서초기황반변성질환과 연관된위험요인연구 한국성인에서초기황반변성질환과 연관된위험요인연구 한국성인에서초기황반변성질환과 연관된위험요인연구 - - i - - i - - ii - - iii - - iv - χ - v - - vi - - 1 - - 2 - - 3 - - 4 - 그림 1. 연구대상자선정도표 - 5 - - 6 - - 7 - - 8 - 그림 2. 연구의틀 χ - 9 - - 10 - - 11 -

More information

- i - - ii - - iii - - iv - - v - - vi - - 1 - - 2 - - 3 - 1) 통계청고시제 2010-150 호 (2010.7.6 개정, 2011.1.1 시행 ) - 4 - 요양급여의적용기준및방법에관한세부사항에따른골밀도검사기준 (2007 년 11 월 1 일시행 ) - 5 - - 6 - - 7 - - 8 - - 9 - - 10 -

More information

김범수

김범수 Analysis of Outcomes after Resection of Sarcomatous Hepatocellular Carcinoma Purpose: Sarcomatous hepatocellular carcinoma (HCC) is rare. Therefore, the clinicopathologic characteristics and prognosis

More information

12이문규

12이문규 Review on Conservative Treatment of Spinal Scoliosis Moon-kyu Lee, O.M.D., Gil-jae Lee, O.M.D., Yun-kyung Song, O.M.D., Hyung-ho Lim, O.M.D. Dept. of Oriental Rehabilitation Medicine College of Oriental

More information

A 617

A 617 Special Issue Diabetic Retinopathy Won Ki Lee, M.D. Department of Ophthalmology The Catholic University of Korea College of Medicine Kangnam St. Mary s Hospital E mail : wklee@catholic.ac.kr Abstract R

More information

49(6)-06.fm

49(6)-06.fm Journal of the Korean Chemical Society 2005, Vol. 49, No. 6 Printed in the Republic of Korea 중학교과학교과서불꽃반응실험에서선스펙트럼관찰의문제점분석및개선연구 ½ Á Á * w w yw (2005. 10. 4 ) An Analysis and Improvement of the Line Spectrum

More information

Abstract Musculoskeletal Symptoms and Related Factors for Nurses and Radiological Technologists Wearing a Lead Apron for Radiation Pro t e c t i o n Jung-Im Yoo, Jung-Wan Koo 1 ) Angio Unit, Team of Radiology,

More information

14(2) 02.fm

14(2) 02.fm J. Korean. Soc. Living. Environ. Sys. Vol. 14, No. 2, pp 117~125(2007) w y y w z sm Ÿ š w œ l ³Á½ * w, **w w w Impact of Photosensor Sensitivity on the Control Performance of a Daylight Dimming System

More information

07.051~058(345).fm

07.051~058(345).fm w wz 8«3y 2008 6 pp. 51 ~ 58 m qp yp š w k sƒ Evaluation of Dynamic Modulus based on Aged Asphalt Binder y*á **Á***Á**** Lee, Kwan-HoÁCho, Kyung-RaeÁLee, Byung-SikÁSong, Yong-Seon Abstract Development

More information

26(3D)-17.fm

26(3D)-17.fm 26ƒ 3D Á 2006 5œ pp. ~ ª y w qp yw k d Predictive Equation of Dynamic Modulus for Hot Mix Asphalt with Granite Aggregates yá½x Á Lee, Kwan-HoÁKim, Hyun-OÁJang, Min-Seok Abstract The presented work provided

More information

51(2)-09.fm

51(2)-09.fm 2007, Vol. 51, No. 2 Printed in the Republic of Korea xw yw w w» e w z Á Á y Áw # Á k * w yw w w w w w # w w w (2006. 10. 30 ) Influences of Current Education Programs for Preservice Chemistry Teachers

More information

23(2) 71.fm

23(2) 71.fm J. of Korean Institute of Fire Sci. & Eng. [ ] Vol. 23, No. 2, 2009 w w w w w w Stud on the Fire Behaviour of Composite Beam with Loading and Unloading ½ *Á û**á½ ***Á½ Sung-Bae Kim* Chang-Nam Lee** Woo-Chul

More information

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있 대한한방부인과학회지 THE JOURNAL OF ORIENTAL OBSTETRICS & GYNECOLOGY VOL.17, NO.2 : 115-122 (2004) 달생산이 초산모 분만시간에 미치는 영향 * 북경한의원, ** 윤산부인과의원, *** 최은림산부인과의원, 상지대학교 한의과대학 부인과학교실 ****, 경희대학교 동서의학대학원 김성준 *****, 윤왕준

More information

레이아웃 1

레이아웃 1 대한위장관기질종양연구회 01 GIST 06 02 11 03 Imatinib 14 04 05 06 07 Sunitinib 32 40 44 48 GIST 6 01 7 GIST Guide book GIST 8 01 9 GIST Guide book GIST (CT) MRI FDG-PET 10 02 11 GIST Guide book 12 02 (Imatinib)

More information

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr May 10~12 2012 Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression from obesity to metabolic syndrome originates in the

More information

19(1)-2(09-06)p fm

19(1)-2(09-06)p fm w wz 9«y Kor. J. Clin. Pharm., Vol. 9, No.. 009 w y Oxaliplatin n w m B Á½ B Á B Áùx BC B ƒm w C ƒm w w w (009 3 Á009 6 Á009 6 0 ) Oxaliplatin-induced Peripheral Neuropathy in Patients with Advanced or

More information

(2)-02(최경자).fm

(2)-02(최경자).fm Res. Plant Dis. 16(2) : 148-152 (2010) Research in Plant Disease The Korean Society of Plant Pathology z w t w sƒ Á½ Á Á yá * w yw yw l Development of Effective Screening Method and Evaluation of Radish

More information

w w l v e p ƒ ü x mw sƒw. ü w v e p p ƒ w ƒ w š (½kz, 2005; ½xy, 2007). ù w l w gv ¾ y w ww.» w v e p p ƒ(½kz, 2008a; ½kz, 2008b) gv w x w x, w mw gv

w w l v e p ƒ ü x mw sƒw. ü w v e p p ƒ w ƒ w š (½kz, 2005; ½xy, 2007). ù w l w gv ¾ y w ww.» w v e p p ƒ(½kz, 2008a; ½kz, 2008b) gv w x w x, w mw gv ª Œª Œ 30ƒ 5A Á 2010 9œ pp. 475 ~ 484 gj p ª v e p p PSC ƒ gv : II. x w Precast Concrete Copings for Precast Segmental PSC Bridge Columns : II. Experiments and Analyses ½kzÁ½ Á zá x Kim, Tae-HoonÁKim,

More information

ECG & EP CASES Young-Keun On, MD, PhD Division of Cardiology, Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea A case of

More information

fm

fm J. Fd Hyg. Safety 20(4), 253 257 (2005) ü w w w Áy»xÁ Á Á Á«Á Áw Á x Á yx Á½ Á½ Á½ t t» t t ƒ q Study on Management of Artificial Flavors in Korea Tal-Soo Lee, Young-Mi Jang, Ki-Hyoung Hong, Sung-Kwan

More information

8(3)-15(p ).fm

8(3)-15(p ).fm w wz J. Kor. Soc. Cloth. Ind. 8«3y, 2006 Vol. 8, No. 3, pp.357-362(2006) w p k sƒ ½ Á Á w w w A Study on the Mechanical and Hand Properties of the Lining Fabrics Myung-Ok Kim, Mi-Kyung Uh and Myung-Ja

More information

fm

fm Journal of the Korea Concrete Institute Vol. 24, No. 1, pp. 079~086, February, 2012 GGGGG http://dx.doi.org/10.4334/jkci.2012.24.1.079 섬유보강콘크리트에묻힌 GFRP 보강근의부착거동에대한섬유영향평가 1) Á½ 1) Á 2) Á 1) * 1) ³ w y lœw

More information

82-02.fm

82-02.fm w y wz 8«( 2y) 00~00, 2005 J. of the Korean Society for Environmental Analysis Calix[6]arene w k š w *Á x Á Á«ƒm w yw, *w w yw Cesium Ion Selective Solid Contact Electrodes Based on Calix[6]arene Won-sik

More information

27(5A)-07(5806).fm

27(5A)-07(5806).fm ª Œª Œ 27ƒ 5A Á 2007 9œ pp. 753 ~ 758 gj pœw gj p { x A New Test Method for Pure Isotropic Flexural Tensile Strength of Concretes Ÿ Á y Á x Zi, GoangseupÁOh, HongseobÁChoi, Jinhyek Abstract Proposed is

More information

590호(01-11)

590호(01-11) T H E K O R E A N D O C T O R S W E E K L Y www.docdocdoc.co.kr I N S I D E 38 3 5 6 7 10 13 28 29 30 31 38 41 42 2 Advertisement Government & Medicine 3 Government & Medicine 4 Government & Medicine Government

More information

전립선암발생률추정과관련요인분석 : The Korean Cancer Prevention Study-II (KCPS-II)

전립선암발생률추정과관련요인분석 : The Korean Cancer Prevention Study-II (KCPS-II) 전립선암발생률추정과관련요인분석 : The Korean Cancer Prevention Study-II (KCPS-II) 전립선암발생률추정과관련요인분석 : The Korean Cancer Prevention Study-II (KCPS-II) - i - - ii - - iii - - iv - - v - - vi - - vii - - viii - - ix - -

More information

16(2)-11(p ).fm

16(2)-11(p ).fm w wz 16«2y Kor. J. Clin. Pharm., Vol. 16, No. 2. 2006 w y wcfubcmpdlfs z sƒ BÁ DÁ DÁ CÁ D B z C w D w w w Retrospective Evaluation for Efficacy and Tolerance of beta-blocker in Heart Failure Patients with

More information

untitled

untitled 대한수혈학회지:제권 제호, 0 한 대학병원의 혈액 폐기 분석 김병철ㆍ서영익ㆍ채금란ㆍ신정원ㆍ최태윤 = Abstract = 순천향대학교 의과대학 서울병원 진단검사의학교실 Analysis of Discarded Blood Components at a University Hospital in Korea Byung Chul Kim, Young Ik Seo, Gum Ran

More information

06.177~184(10-079).fm

06.177~184(10-079).fm Journal of the Korea Concrete Institute Vol. 23, No. 2, pp. 177~184, April, 2011 GGGGG DOI 10.4334/JKCI.2011.23.2.177 x w w MRS w p s y 1) Á z 2) Á x 3) * 1) wû w œw 2) w œw 3) w Nonlinear Analysis for

More information

<30312DC0CCC7E2B9FC2E666D>

<30312DC0CCC7E2B9FC2E666D> 균류의다양성과역할 이향범 û w œw 머리말 k w š ³ q š yw < Ð >» w ww k w w v š q w Á Á w tyw š 2QKPVKPI CPF *[FG ú ƒ x %QPXGPVKQP QP $KQNQIKECN &KXGTUKV[ %$&» w w ««wš y w» š x ƒ w œ ƒ» ƒ œsw w ³ wš ù š y š ƒ t š ƒ wš»ƒ

More information

歯14.양돈규.hwp

歯14.양돈규.hwp : The Korean Journal of Counseling and Psychotherapy 2003. Vol. 15, No. 3, 615-631. 1 2 3 1,410.,, ( ),., ( 69%),.,, ( ), ( ).,,.., ( ).,. :,,. :, (390-711) 21-1, : 043-649-1362 E-mail : ydk9498@hanmail.net

More information

10.063~070(B04_윤성식).fm

10.063~070(B04_윤성식).fm J. of Advanced Engineering and Technology Vol. 1, No. 1 (2008) pp. 63-70 Mg-3%Al-1%Zn w ƒœ» y Á x*á **Á Á w œw *w s l I ûer ** t Effect of Thermomechanical Treatment on Microstructure and Mechanical Properties

More information

<35BFCFBCBA2E687770>

<35BFCFBCBA2E687770> 주요개념 : 컴퓨터음란물 접촉자, 성지식, 성태도 남자중학생의 컴퓨터음란물 접촉자와 비접촉자간의 성지식과 태도의 차이 김 영 혜* 이 화 자** 정 향 미*** 1. 연구의 필요성 한국은 I. 서 론 1960 년대 이후부터 시작된 돌진적 산업화 ( 한 상진, 1996) 로 인하여 경제적 부흥을 이루어 집집마다 TV 수상기를 가질 수 있게 되었고 최근에는 PC보급율

More information

14.fm

14.fm Journal of the Korean Ceramic Society Vol. 44, No. 2, pp. 93~97, 2007. Preparation of High Purity Si Powder by SHS Chang Yun Shin, Hyun Hong Min, Ki Seok Yun, and Chang Whan Won Engineering Research Center

More information

51(4)-13.fm

51(4)-13.fm Journal of the Korean Chemical Society 2007, Vol. 51, No. 4 Printed in the Republic of Korea w x - w y *Á š w w w yw (2007. 3. 28 ) Case Study on Verbal Interactions of Teacher-Small Group StudentsG in

More information

<5B31362E30332E31315D20C5EBC7D5B0C7B0ADC1F5C1F8BBE7BEF720BEC8B3BB2DB1DDBFAC2E687770>

<5B31362E30332E31315D20C5EBC7D5B0C7B0ADC1F5C1F8BBE7BEF720BEC8B3BB2DB1DDBFAC2E687770> 2016 지역사회 통합건강증진사업 안내 - 지역사회 중심 금연지원 서비스 - 2016. 3. 주요변경사항 5 1부 국가 금연정책 추진 및 현황 Ⅰ. 국가 금연정책 개요 1. 금연정책의 배경 및 필요성 11 2. 세계 금연정책 동향 20 3. 우리나라 금연정책 추진경과 24 4. 2016년도 금연정책 추진방향 31 Ⅱ. 국가 금연사업 현황 1. 흡연자 금연지원서비스

More information

- i - - ii - - iii - - iv - - v - - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - α α - 20 - α α α α α α - 21 - - 22 - - 23 -

More information

19(1)-1(09-01)p.1-17.fm

19(1)-1(09-01)p.1-17.fm w wz 19«1y Kor. J. Clin. Pharm., Vol. 19, No. 1. 2009 ü t y BÁ CÁ wc B Ÿ w w w C w w w (2009 2 5 Á2009 6 10 Á2009 6 25 ) Analysis of Drug Interaction Information Young Sook Lee, Ji Seon Lee and Sukhyang

More information

15(2)-07.fm

15(2)-07.fm J. Korean. Soc. Living. Environ. Sys. Vol. 15, No. 2, pp 145~154(2008) w y y w z 15 «2 y 2008 ³ l w sm ½ Á yáy * w y w, ** w w Recommended Sensitivity of a Fully-shielded Photosensor for a Daylight Dimming

More information